6751 - 6760 of 9038 Results
Title
Year
-
OPENTitle: Lysosome and Inflammatory Defects in GBA1‐Mutant Astrocytes Are Normalized by LRRK2 InhibitionJournal Name: Movement DisordersPublisher: WileyVol: 35Issue #: 5Start Page: 760End Page: 773Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.27994Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/8167931Citation Count: 108
- GBA variation and susceptibility to multiple system atrophy2020RESTRICTEDTitle: GBA variation and susceptibility to multiple system atrophyJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 77Issue #:Start Page: 64End Page: 69Publication Date:Open Access(OA) Status: RESTRICTEDLicense: other-oaDOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.06.007Citation Count: 26
-
OPENTitle: Hemispheric lateralization of dopamine transporter binding in Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 141Issue #:Start Page: 108076End Page: 108076Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2025.108076Best OA location URL: https://doi.org/10.1016/j.parkreldis.2025.108076Citation Count: 0
-
OPENTitle: NeuroBooster Array: A Genome‐Wide Genotyping Platform to Study Neurological Disorders Across Diverse PopulationsJournal Name: Movement DisordersPublisher: WileyVol: 39Issue #: 11Start Page: 2039End Page: 2048Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/mds.29902Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mds.29902Citation Count: 38
- Pyridine-Fused 2-Pyridones via Povarov and A3 Reactions: Rapid Generation of Highly Functionalized Tricyclic Heterocycles Capable of Amyloid Fibril Binding2019RESTRICTEDTitle: Pyridine-Fused 2-Pyridones via Povarov and A3 Reactions: Rapid Generation of Highly Functionalized Tricyclic Heterocycles Capable of Amyloid Fibril BindingJournal Name: The Journal of Organic ChemistryPublisher: American Chemical Society (ACS)Vol: 84Issue #: 7Start Page: 3887End Page: 3903Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1021/acs.joc.8b03015Citation Count: 22
-
OPENTitle: Pooled analysis of iron-related genes in Parkinson's disease: Association with transferrinJournal Name: Neurobiology of DiseasePublisher: Elsevier BVVol: 62Issue #:Start Page: 172End Page: 178Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.nbd.2013.09.019Best OA location URL: https://www.sciencedirect.com/science/article/pii/S0969996113002659Citation Count: 87
-
OPENTitle: Radiolabeled Aminopyrazoles as Novel Isoform Selective Probes for pJNK3 QuantificationJournal Name: ACS Medicinal Chemistry LettersPublisher: American Chemical Society (ACS)Vol: 13Issue #: 10Start Page: 1606End Page: 1614Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1021/acsmedchemlett.2c00278Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/9575163Citation Count: 4
- Ondansetron, a highly selective 5-HT3 receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease2020RESTRICTEDTitle: Ondansetron, a highly selective 5-HT3 receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's diseaseJournal Name: European Journal of PharmacologyPublisher: Elsevier BVVol: 871Issue #:Start Page: 172914End Page: 172914Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.ejphar.2020.172914Citation Count: 21
-
OPENTitle: Prevalence and Risk Factors for Double Vision in Parkinson DiseaseJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 8Issue #: 5Start Page: 709End Page: 712Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mdc3.13220Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.13220Citation Count: 12
- A Phase 2A Trial of the Novel mGluR5‐Negative Allosteric Modulator Dipraglurant for Levodopa‐Induced Dyskinesia in Parkinson's Disease2016RESTRICTEDTitle: A Phase 2A Trial of the Novel mGluR5‐Negative Allosteric Modulator Dipraglurant for Levodopa‐Induced Dyskinesia in Parkinson's DiseaseJournal Name: Movement DisordersPublisher: WileyVol: 31Issue #: 9Start Page: 1373End Page: 1380Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1002/mds.26659Citation Count: 140